Tokyo-based Eisai will co-promote three Novartis inhaled COPD therapies in Japan with Novartis Pharma K.K. Starting on December 1, 2011, both companies will promote Onbrez indacaterol inhalation capsules, with Novartis targeting flagship and university hospitals and Eisai focusing on general hospitals and clinicians. Onbrez was launched in Japan in September 2011. … [Read more...] about Eisai to co-promote Novartis COPD drugs in Japan
Business
Single batch of Omnaris nasal spray recalled in Hong Kong
According to the Hong Kong Department of Health (DH), Nycomed (Hong Kong) has voluntarily recalled a batch of Omnaris ciclesonide nasal spray due "a quality defect." The product, from batch number 137930, was manufactured in Germany by Nycomed Gmbh in August 2010. The DH says that it was notified by Nycomed Gmbh that it had found pinholes in some of the foil … [Read more...] about Single batch of Omnaris nasal spray recalled in Hong Kong
Mylan gets Pfizer’s respiratory delivery platform, acquires global rights to generic Diskus products
US generics company Mylan Inc. has obtained worldwide rights to develop, manufacture and commercialize Pfizer's generic equivalent to GlaxoSmithKline's Advair Diskus and Seretide Diskus products for asthma and COPD using Pfizer's proprietary dry powder inhalation technology. Pfizer will also allow Mylan to develop and commercialize other DPI products using the … [Read more...] about Mylan gets Pfizer’s respiratory delivery platform, acquires global rights to generic Diskus products
Catalent joins IPAC-RS
CRO Catalent Pharma Solutions has joined the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS), a consortium of companies involved in the development, manufacture, and marketing of OINDPs, whose mission is "to advance scientifically driven approaches to enhancing product quality of inhaled and intranasal drug products." Other IPAC-RS … [Read more...] about Catalent joins IPAC-RS
Novartis warns of delays in US approval process for NVA237 and QVA149
In its third quarter results for 2011, Novartis announced that, "In the US, NVA237 will require additional clinical data to support submission and thus will be delayed." Furthermore, the company warned, "The changes to the US NVA237 program will similarly impact approval timing for QVA149 in the US where additional clinical studies will be required. The QVA149 … [Read more...] about Novartis warns of delays in US approval process for NVA237 and QVA149
New scientific advisory board for Prosonix
Ken Cunningham, who recently joined the board of UK pharmaceutical and particle engineering company Prosonix, will lead the company's new scientific advisory board. Joining Cunningham on Prosonix's SAB are: Peter Barnes, Professor of Thoracic Medicine and Head of Airway Disease, National Heart and Lung Institute, and Honorary Consultant Physician, Royal Brompton … [Read more...] about New scientific advisory board for Prosonix
Acton Pharmaceuticals will develop and market Nasacort HFA in US
Massachusetts respiratory pharmaceutical company Acton Pharmaceuticals has entered into a licensing agreement with Sanofi US that gives Acton exclusive US rights to develop and market prescription Nasacort HFA triamcinolone acetonide nasal aerosol for the treatment of nasal allergy symptoms due to seasonal or perennial rhinitis in adults and children 6 years old and … [Read more...] about Acton Pharmaceuticals will develop and market Nasacort HFA in US
Impel gets new funding for development of intranasal delivery
Impel NeuroPharma has announced new funding for development of its Pressurized Olfactory Delivery (POD) device from a variety of sources. The company says that in addition to closing on over a half million dollars of equity investment from "angel investors experienced in the pharmaceutical and medical device industries," it has also entered into collaborations with … [Read more...] about Impel gets new funding for development of intranasal delivery
Hovione and Bend agree to collaborate on inhalation technologies, manufacturing
Two experts in particle manufacturing for inhaled dry powder formulations, Hovione and Bend research, have entered into a non-exclusive collaboration in which they will have access to each other's technologies. The partnership also gives Bend access to Hovione's commercial manufacturing capabilities in Portugal, Ireland, China, and the US. “Hovione has world-class … [Read more...] about Hovione and Bend agree to collaborate on inhalation technologies, manufacturing
Insight recalls lot of Nostrilla nasal decongestant spray
Insight Pharmaceuticals has voluntarily recalled a single lot of its Nostrilla oxymetazoline hydrochloride nasal spray due to possible contamination with Burkholderia cepacia bacteria. Nostrilla is available without prescription, and lot #11G075, which consisted of 34,092 1/2-oz bottles, was distributed in US retail stores and pharmacies. According to Insight, it has … [Read more...] about Insight recalls lot of Nostrilla nasal decongestant spray